The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.EBI
Gilead Sciences
Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2).EBI
University of Tennessee Health Science Center
CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).EBI
University of Tennessee Health Sciences Center
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.EBI
University of Tennessee Health Science Center
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.EBI
University of Urbino
Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines.EBI
Leiden University
Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter.EBI
University of Tennessee Health Sciences Center
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.EBI
National Institute of Diabetes
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.EBI
National Institute of Diabetes
Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors.EBI
University of Tennessee Health Sciences Center
Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues.EBI
Ulm University
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.EBI
University of Tennessee Health Sciences Center
Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors.EBI
University of Tennessee Health Sciences Center
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.EBI
National Institute of Diabetes & Digestive & Kidney Diseases
A closer look at NEBI
Monash University Malaysia
Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups.EBI
Leiden University
Development of potent CPP6-gemcitabine conjugates against human prostate cancer cell line (PC-3).EBI
University of Porto
Indolinone Inhibitors of ENT1 for the Treatment of Schizophrenia.EBI
Dart Neuroscience
Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatmentBDB
Fondazione Istituto Italiano Di Tecnologia
Biaryl kinase inhibitorsBDB
Bristol-Myers Squibb